Nazione: Canada
Lingua: inglese
Fonte: Health Canada
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE)
BIOMED PHARMA
A10BH01
SITAGLIPTIN
50MG
TABLET
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50MG
ORAL
100
Prescription
Active ingredient group (AIG) number: 0152414003; AHFS:
APPROVED
2023-11-16
_ _ _Product Monograph - Bio-SITAGLIPTIN _ _Page 1 of 57_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR BIO-SITAGLIPTIN sitagliptin tablets Tablets, 25, 50 and 100 mg sitagliptin (as sitagliptin phosphate anhydrous), Oral House Standard ATC Code: A10BH01 Dipeptidyl peptidase 4 (DPP-4) inhibitors Submission Control Number: 280289 Biomed Pharma 1B-9450 Boulevard Langelier Montreal, Quebec H1P3H8, Canada Date of Initial Authorization: NOV 16, 2023 _Product Monograph - Bio-SITAGLIPTIN Page _2_ of _57 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of sitagliptin in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. ...................................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.1 Dosing Considerations .............................................................................................. 4 4.2 Recommended Dose and Dosage Adju Leggi il documento completo